investors.curis.com Open in urlscan Pro
2606:4700::6811:cd9f  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * About
   * Company Overview
   * History
   * Management
   * Board of Directors
 * Collaborations
   * Partner Collaborations
   * Scientific & Research Collaborations
 * Patients
   * Patients Overview
   * About Clinical Studies
   * Studies Now Enrolling
 * Pipeline
   * Pipeline Overview
   * CA-4948
   * CI-8993
   * Fimepinostat
   * CA-170
   * CA-327
   * Erivedge®
 * Investors
   * Overview
   * Press Releases
   * Events & Presentations
   * Corporate Governance
     * Management
     * Board of Directors
     * Committee Composition
     * Contact the Board
   * Financial Information
     * SEC Filings
     * Annual Reports
     * Quarterly Results
     * Key Ratios
     * Financial Statements
   * Stock Performance
     * Interactive Chart
     * Historical Stock Lookup
     * Investment Calculator
     * Analyst Coverage
     * Ownership Profile
   * Contact Us
 * Careers
   * Life at Curis
   * Open Positions
   * Benefits
 * Contact

 * About
   * Company Overview
   * History
   * Management
   * Board of Directors
 * Collaborations
   * Partner Collaborations
   * Scientific & Research Collaborations
 * Patients
   * Patients Overview
   * About Clinical Studies
   * Studies Now Enrolling
 * Pipeline
   * Pipeline Overview
   * CA-4948
   * CI-8993
   * Fimepinostat
   * CA-170
   * CA-327
   * Erivedge®
 * * Overview
   * Press Releases
   * Events & Presentations
   * Corporate Governance
   * Financial Information
   * Stock Performance
   * Contact Us
 * Careers
   * Life at Curis
   * Open Positions
   * Benefits
 * Contact


INVESTOR RELATIONS

Curis is a biotechnology company focused on the development of innovative
therapeutics for the treatment of cancer.


Press Releases
Investor Alerts
Aug 18, 2022
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib

Curis working with clinical sites to resume enrollment Preliminary clinical data
update expected in 2023 LEXINGTON, Mass., Aug. 18, 2022 /PRNewswire/ -- Curis,
Inc. (NASDAQ: CRIS), a biotechnology...

Aug 4, 2022
Curis Reports Second Quarter 2022 Financial Results and Business Update

Presented encouraging clinical data for the combination of emavusertib plus
ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential
for overcoming ibrutinib resistance at...

View all press releases >>

Events & Presentations
Curis Reports Second Quarter 2022 Financial Results
Thursday, August 4, 2022
4:30pm - 5:30pm EDT
2022 Jefferies Global Healthcare Conference
Thursday, June 9, 2022
11:00am - 12:00pm EDT

View all events & presentations >>

Latest Presentation

View the latest presentation

Investor Alerts

Receive the latest alerts via email.

Sign up

Contact IR

Curis, Inc.
128 Spring Street
Building C- Suite 500
Lexington, MA 02421
Phone: 617-503-6500
Email: info@curis.com

Transfer Agent

Computershare
250 Royall Street
Canton, MA 02021
URL: www.computershare.com/investor
Phone: 877-810-2248

This website contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements regarding
Curis' future financial position, business strategy and plans and objectives of
management for future operations. We may use such words as "believes,"
"expects," "anticipates," "plans," "estimates," and similar expressions to
identify these forward-looking statements. There are a number of important
factors that could cause Curis' actual results to differ materially from these
indicated by such forward-looking statements, including those risk factors
identified in the filings that Curis' makes from time to time with the SEC
(click here to access SEC filings and risk factors contained herein). Curis
disclaims any intention or obligation to update any forward-looking statements
as a result of developments occurring after the date such statement was first
made.

© Curis, Inc. 2019 - All Rights Reserved
 * Terms of Use
 * Privacy Policy

This website uses cookies to improve your browsing experience and analyze site
traffic. By using our site, you consent to our use of cookies, in accordance
with our privacy policies. I Understand

 * About
   * Company Overview
   * History
   * Management
   * Board of Directors
 * Collaborations
   * Partner Collaborations
   * Scientific & Research Collaborations
 * Patients
   * Patients Overview
   * About Clinical Studies
   * Studies Now Enrolling
 * Pipeline
   * Pipeline Overview
   * CA-4948
   * CI-8993
   * Fimepinostat
   * CA-170
   * CA-327
   * Erivedge®
 * Investors
   * Overview
   * Press Releases
   * Events & Presentations
   * Corporate Governance
   * Financial Information
   * Stock Performance
   * Contact Us
 * Careers
   * Life at Curis
   * Open Positions
   * Benefits
 * Contact
 *